VIR
NASD Vir Biotechnology, Inc.$11.13 ↓ -0.05 (-0.44%) Trading Down from the previous close of $11.18
- YTD change
- +84.58%
- vs 20-day SMA
- +2.13%
- vs 200-day SMA
- +23.98%
Price ranges
Price & Performance
+2.16 (+23.95%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 92.1% away from all-time highs of $141.01
- VIR is up 85% since the beginning of the year
- VIR is up 95% over the past 12 months
- VIR is down 4% over the past 1 month
- 15% of all VIR investors are betting against VIR
VIR reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +96.1%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- +0.36%
- vs 8-day SMA
- +2.13%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
